Koza Altin Welcomes English High Court’s Rejection of Akin Ipek’s Bid to Use Company Money to Fund Extradition Fight
2.7.2018 14:18:00 EEST | Business Wire | Press release
2nd July 2018 - An English High Court judge has delivered another legal blow to Akin Ipek – blocking his attempt to use Koza Ltd to fund his attempts to resist extradition to Turkey, where he faces criminal charges.
Mr Justice Morgan also ruled that, contrary to Mr Ipek’s own submissions, he appears to have sufficient funds of his own to pay his legal fees. The Judge made clear that Koza Ltd’s purpose was not to fund Mr Ipek’s personal legal battles when he can afford to do so himself. The ruling came after bank statements and other evidence were placed before the court indicating that tens of millions of dollars worth of funds had been hidden away by Mr Ipek.
Koza Ltd is a UK based private company which is wholly-owned by Koza Altin, a publicly-listed company in Ankara. Koza Altin has initiated a process to remove Mr Hamdi Akin Ipek from the Board of Koza Ltd. Mr Ipek is resisting his removal in the English Courts, and the issue is the subject of ongoing litigation.
This month’s ruling relates to an attempt by Mr Ipek in the meantime to use Koza Ltd’s funds to finance a separate attempt on his part to resist extradition to Turkey. This attempt has now been blocked by Mr Justice Morgan.
Koza Altin’s case in the underlying litigation is that Mr Ipek and Koza Ltd are seeking to prevent Koza Altin from exercising its rights as shareholder of Koza Ltd. Koza Altin is seeking the removal of Mr Ipek as a director of Koza Ltd in order to protect Koza Altin and its assets for the benefit of its shareholders and in accordance with its regulatory obligations. Specifically, the company is taking action to ensure that around £60m of shareholders’ capital held by Koza Ltd cannot be improperly taken out of the company and used for Mr Ipek’s personal interests.
This is a matter of sensible corporate governance, entirely consistent with Koza Altin’s responsibilities as an entity strictly regulated by the relevant independent authorities. Koza Altin takes seriously its obligations under capital markets laws and other laws and regulations in Turkey. It will take whatever steps are necessary to protect shareholders.
The action is taken for the benefit of all of Koza Altin’s shareholders - including funds, banks and other Turkish and international investors who directly own 30% of Koza Altin and indirectly own a majority of 58%. Koza Altin also follows the requirements of the Capital Market Board which is the regulatory authority for the Turkish capital markets.
Koza Altin’s position is that the changes made to Koza Ltd’s constitution by Mr Ipek in September 2015 were invalid and improper. Specifically, he bestowed upon himself and his brother, at a total cost of £2, rights to control a company wholly owned by Koza Altin, and in possession of then around £60m, whose transfer from Koza Altin Mr Ipek had previously arranged. This move caused Koza Altin to lose control over Koza Ltd completely. The need to take legal action to protect Koza Altin and its public shareholders in this situation is obvious. It believes the UK court will uphold its position.
Contrary to what Mr Ipek attempts to claim in these proceedings, neither Koza Altin nor any of its assets has been seized or expropriated by the Turkish state. The changes at Koza Altin’s management have not damaged the company’s interests in any way, and have been welcomed by investors, including a number of international institutional investors. This is clearly evidenced by the company’s share price, which has risen since Mr Ipek’s removal.
The court-imposed changes in management at Koza Altin are designed to preserve assets and evidence. The former trustees were appointed in October 2015 by the Turkish Criminal Court, in accordance with the Turkish Criminal Procedure Code, on the basis of a suspicion by the court of money laundering and terrorist financing.
Hugo Plowman, partner at Mishcon de Reya and Koza Altin’s legal adviser, said:
“These proceedings ultimately derive from an attempt by Mr Ipek to resist his removal from the Board of Koza Ltd. The process of removing him was initiated entirely lawfully in 2016 by Koza Altin, Koza Ltd’s parent company, and is the subject of ongoing litigation. We are confident in our legal case and welcome this latest ruling in Koza Altin’s favour.
“Koza Altin refutes the various allegations put forward by Mr Ipek in resisting his removal. In the meantime Mr Justice Morgan’s ruling makes clear that he needs to pay the costs relating to the extradition process himself, and stop trying to use Koza Ltd as his personal piggy-bank.”
ENDS
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180702005455/en/
Contact information
Media enquiries:
Powerscourt
Conal Walsh/Isabelle Saber
+44
(0)20 7250 1446
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 17:28:00 EEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 16:00:00 EEST | Press release
Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading transformative and meaningful customer experiences. These leading organizations are turning everyday interactions into seamless, cross-channel journeys that deliver meaningful business impact and
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 16:00:00 EEST | Press release
Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On the demand side, with smart meter integration, Predict+ models each meter individually and performs extensive calculations on actual, historical, and average data to acc
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 15:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)4.5.2026 15:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrated safety, efficacy and tolerability profiles comparable to HYQVIA, an established SCIG 10% facilitated with hyaluronidase. These findings support the potential of TAK-881 to deliver the required immunoglobulin (IG) dose for PID patients in half the volume of HYQVIA, reducing infusion duration while maintaining flexible, up to once-monthly dosing for patients (every three or four weeks for PID). The TAK-881-3001 clinical trial ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
